This review examines whether the application of pre-emption rights when new shares are issued may hinder certain public companies from raising finance flexibly for innovation and growth and, as far as there are problems, to recommend possible solutions.
The study follows on from representations, primarily from the biotechnology industry, that current application of pre-emption rights in the UK makes it difficult and expensive for companies to finance research and product development.